Vuković Vlasta, Lovrencić-Huzjan Arijana, Bosnar-Puretić Marijana, Demarin Vida
University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, Croatia.
Acta Clin Croat. 2009 Jun;48(2):145-51.
Migraine is often a chronic and disabling disorder. The objective of our study was to assess the efficacy and safety of gabapentin in the prophylaxis of migraine in patients refractory to other prophylactic treatments. The study included 67 migraine patients, 55 women and 12 men; 52 patients completed this prospective, open-label study. Patients were given 900-1800 mg of gabapentin in 3 doses; the mean duration of treatment was 7.2 months. Reduction in the number of days with headache, pain intensity and number of acute medications was assessed through patient diary. The mean number of migraine days/4 weeks was reduced from 15.8 to 8.6, yielding a reduction of 7.2 migraine days/4 weeks (P=0.001). Pain intensity was reduced by 25% in 14 (26.9%), by 50% in 29 (55.7%) and by 75% in three (5.7%) patients, whereas no improvement was reported by six (11.5%) patients at the end of follow up. A significant reduction was recorded in acute medication use (P=0.001). Adverse events were reported by 32/67 (47.8%) patients, in 15 (22.4%) of them causing discontinuation of the drug. The most frequently reported adverse events were drowsiness, dizziness and slowness. Prophylactic treatment with gabapentin was found to be associated with a significant reduction in the number of days with headache, use of acute medications and pain intensity.
偏头痛通常是一种慢性致残性疾病。我们研究的目的是评估加巴喷丁对其他预防性治疗无效的偏头痛患者进行预防的疗效和安全性。该研究纳入了67例偏头痛患者，其中55例女性，12例男性；52例患者完成了这项前瞻性、开放标签研究。患者分3次服用900 - 1800毫克加巴喷丁；平均治疗时长为7.2个月。通过患者日记评估头痛天数、疼痛强度和急性药物使用次数的减少情况。偏头痛天数/4周的平均数从15.8天降至8.6天，即减少了7.2个偏头痛天数/4周（P = 0.001）。14例（26.9%）患者疼痛强度降低了25%，29例（55.7%）患者降低了50%，3例（5.7%）患者降低了75%，而6例（11.5%）患者在随访结束时未见改善。急性药物使用量显著减少（P = 0.001）。32/67例（47.8%）患者报告了不良事件，其中15例（22.4%）因不良事件停药。最常报告的不良事件为嗜睡、头晕和反应迟缓。发现加巴喷丁预防性治疗与头痛天数、急性药物使用量和疼痛强度的显著减少相关。
